Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ACHV Stock Forecast 2025-2026
$3.14
Current Price
$103.36M
Market Cap
Buy 6
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ACHV Price Targets
+855.4%
To High Target of $30.00
+345.9%
To Median Target of $14.00
+218.5%
To Low Target of $10.00
ACHV Price Momentum
-5.4%
1 Week Change
-5.1%
1 Month Change
-34.3%
1 Year Change
-10.8%
Year-to-Date Change
-40.9%
From 52W High of $5.31
+70.7%
From 52W Low of $1.84
📊 TOP ANALYST CALLS
Did ACHV Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Achieve Life Sciences is one of their latest high-conviction picks.
Latest ACHV Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, ACHV has a bullish consensus with a median price target of $14.00 (ranging from $10.00 to $30.00). Currently trading at $3.14, the median forecast implies a 345.9% upside. This outlook is supported by 6 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ACHV Analyst Ratings
6
Buy
0
Hold
0
Sell
ACHV Price Target Range
Low
$10.00
Average
$14.00
High
$30.00
Current: $3.14
Latest ACHV Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ACHV.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 14, 2024 | Rodman & Renshaw | Brandon Folkes | Buy | Initiates | $12.00 |
| Sep 27, 2024 | Raymond James | Gary Nachman | Strong Buy | Initiates | $20.00 |
| Aug 15, 2024 | Oppenheimer | Francois Brisebois | Outperform | Reiterates | $11.00 |
| May 13, 2024 | Oppenheimer | Francois Brisebois | Outperform | Maintains | $11.00 |
| Apr 17, 2024 | JonesTrading | Justin Walsh | Buy | Initiates | $20.00 |
| Apr 1, 2024 | Oppenheimer | Francois Brisebois | Outperform | Reiterates | $18.00 |
| Mar 5, 2024 | Lake Street | Thomas Flaten | Buy | Maintains | $11.00 |
| Dec 12, 2023 | Oppenheimer | Francois Brisebois | Outperform | Maintains | $18.00 |
| Jun 1, 2023 | Lake Street | Buy | Maintains | $0.00 | |
| May 31, 2023 | Lake Street | Thomas Flaten | Buy | Maintains | $19.00 |
| May 10, 2023 | Lake Street | Thomas Flaten | Buy | Maintains | $22.00 |
| Mar 17, 2023 | Oppenheimer | Francois Brisebois | Outperform | Reiterates | $17.00 |
| Nov 16, 2022 | Maxim Group | Jason McCarthy | Buy | Maintains | $8.00 |
| Oct 4, 2021 | Alliance Global Partners | James Molloy | Buy | Initiates | $25.00 |
| Jun 23, 2021 | Oppenheimer | Outperform | Initiates | $0.00 | |
| Nov 25, 2020 | Lake Street | Buy | Initiates | $0.00 | |
| Nov 25, 2020 | Maxim Group | Buy | Initiates | $0.00 | |
| Nov 25, 2020 | H.C. Wainwright | Buy | Initiates | $0.00 | |
| Sep 17, 2020 | Lake Street | Buy | Initiates | $0.00 | |
| Feb 25, 2020 | HC Wainwright& Co. | Buy | Initiates | $0.00 |
Achieve Life Sciences Inc. (ACHV) Competitors
The following stocks are similar to Achieve Life Sciences based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ACHV
Achieve Life Sciences
mkt cap
112.73M
Achieve Life Sciences Inc. (ACHV) Financial Data
Achieve Life Sciences Inc. has a market capitalization of $103.36M with a P/E ratio of -2.5x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -154.5%.
Valuation Metrics
Market Cap
$103.36M
Enterprise Value
$90.08M
P/E Ratio
-2.5x
PEG Ratio
-2.6x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+21.3%
Current Ratio
3.5x
Debt/Equity
96.9x
ROE
-154.5%
ROA
-59.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Achieve Life Sciences Inc. (ACHV) Business Model
About Achieve Life Sciences Inc.
What They Do
Biotechnology firm focused on addiction cessation therapies.
Business Model
The company develops and commercializes therapies, specifically cytisinicline, to assist individuals in quitting smoking. It generates revenue through the advancement of its products in clinical trials and subsequent regulatory approvals, targeting a significant market driven by the need for effective smoking cessation solutions.
Additional Information
With its headquarters in the U.S., Achieve Life Sciences is positioned in the healthcare and pharmaceutical sectors, addressing public health challenges related to tobacco-related diseases. The company is committed to delivering innovative health solutions and improving addiction management strategies.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
25
CEO
Dr. Richard A. B. Stewart
Country
Canada
IPO Year
1995
Website
www.achievelifesciences.comAchieve Life Sciences Inc. (ACHV) Latest News & Analysis
Latest News
Quick Summary
Achieve Life Sciences (ACHV) is advancing its smoking cessation drug, cytisinicline, in late-stage trials, addressing a key market need. Despite potential FDA challenges, it presents a favorable risk/reward profile.
Why It Matters
Achieve Life Sciences' cytisinicline shows promise in the smoking cessation market, offering growth potential amid low valuation, appealing to investors seeking high-risk, high-reward opportunities.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Achieve Life Sciences (NASDAQ: ACHV) will present at the Jefferies Global Healthcare Conference from June 3-5, 2025, focusing on its cytisinicline treatment for nicotine dependence.
Why It Matters
Achieve Life Sciences is showcasing its nicotine dependence treatment at a major healthcare conference, potentially attracting investor interest and impacting stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Achieve Life Sciences will present additional findings from its Phase 3 ORCA-3 study on cytisinicline for smoking cessation at the ATS Conference on May 20, 2025, highlighting its effects on nicotine cravings.
Why It Matters
The presentation of positive Phase 3 study results for cytisinicline could boost Achieve Life Sciences' stock, indicating potential market success and attracting investor interest in smoking cessation products.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Achieve Life Sciences, Inc. will host its Q1 2025 Earnings Conference Call on May 13, 2025, at 8:30 AM ET, featuring key company executives and analysts.
Why It Matters
The earnings call provides insights into Achieve Life Sciences' financial health and strategic direction, influencing stock performance and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Achieve Life Sciences plans to submit a New Drug Application for cytisinicline to the FDA in June 2025, as announced during their Q1 2025 financial results conference call.
Why It Matters
The planned NDA submission for cytisinicline signals potential FDA approval, influencing market confidence and stock performance for Achieve Life Sciences. Positive outcomes could boost revenues.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Achieve Life Sciences, Inc. will report its Q1 2025 financial results and update on cytisinicline's development for nicotine dependence on May 13, 2025, at 8:30 AM EDT.
Why It Matters
Achieve Life Sciences' upcoming financial report and update on cytisinicline's development could impact stock performance, signaling progress or setbacks in a key treatment for nicotine dependence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ACHV Stock
What is Achieve Life Sciences Inc.'s (ACHV) stock forecast for 2025?
Based on our analysis of 8 Wall Street analysts, Achieve Life Sciences Inc. (ACHV) has a median price target of $14.00. The highest price target is $30.00 and the lowest is $10.00.
Is ACHV stock a good investment in 2025?
According to current analyst ratings, ACHV has 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.14. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ACHV stock?
Wall Street analysts predict ACHV stock could reach $14.00 in the next 12 months. This represents a 345.9% increase from the current price of $3.14. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Achieve Life Sciences Inc.'s business model?
The company develops and commercializes therapies, specifically cytisinicline, to assist individuals in quitting smoking. It generates revenue through the advancement of its products in clinical trials and subsequent regulatory approvals, targeting a significant market driven by the need for effective smoking cessation solutions.
What is the highest forecasted price for ACHV Achieve Life Sciences Inc.?
The highest price target for ACHV is $30.00 from at , which represents a 855.4% increase from the current price of $3.14.
What is the lowest forecasted price for ACHV Achieve Life Sciences Inc.?
The lowest price target for ACHV is $10.00 from at , which represents a 218.5% increase from the current price of $3.14.
What is the overall ACHV consensus from analysts for Achieve Life Sciences Inc.?
The overall analyst consensus for ACHV is bullish. Out of 8 Wall Street analysts, 6 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $14.00.
How accurate are ACHV stock price projections?
Stock price projections, including those for Achieve Life Sciences Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 19, 2025 3:09 PM UTC